Published by Alexander Bueso on 10th October 2019
(Sharecast News) - Analysts at RBC reiterated their recommendation to 'buy' shares of Sarepta, expressing confidence in the efficacy of the gene therapy specialist's muscular distrophy programmes, telling clients that they believed they would "ultimately succeed".
URL: http://www.digitallook.com/dl/news/story/29695156/...